# A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

> **NCT02718911** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 72 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** LY3022855
- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT02718911
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-16
- **Primary completion:** 2018-12-14
- **Final completion:** 2018-12-14
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2023-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02718911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02718911, "A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02718911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*